Marker Therapeutics Inc. (NASDAQ: MRKR)
$5.89
+0.0401 ( +0.69% ) 1.6K
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Market Data
Open
$5.89
Previous close
$5.85
Volume
1.6K
Market cap
$53.32M
Day range
$5.83 - $6.15
52 week range
$2.40 - $9.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 36 | Jan 08, 2024 |
8-k | 8K-related | 14 | Dec 11, 2023 |
8-k | 8K-related | 12 | Nov 20, 2023 |
8-k | 8K-related | 14 | Nov 09, 2023 |
10-q | Quarterly Reports | 66 | Nov 09, 2023 |
8-k | 8K-related | 14 | Sep 11, 2023 |
8-k | 8K-related | 14 | Aug 14, 2023 |
10-q | Quarterly Reports | 67 | Aug 14, 2023 |
8-k | 8K-related | 14 | Aug 07, 2023 |
8-k | 8K-related | 14 | Jul 10, 2023 |